What Yi Fei Treats: Main Uses and Benefits

Yi Fei (Loratadine) is commonly used across domains where additional symptomatic support is needed for conditions involving inflammatory or irritative states driven by allergies.

The medicine may be part of symptomatic management for symptom clusters associated with allergic rhinitis (including seasonal hay fever and year-round allergies), allergic conjunctivitis, and Chronic Idiopathic Urticaria (hives). It is applied during phases when symptoms become more noticeable, and is relevant for easing manifestations such as excessive sneezing, a runny nose, itching of the eyes and nose, and dermal itching.

“This use contributes to easing the overall symptom load during periods of heightened symptoms.”

This supportive relief may assist with managing symptoms that create noticeable physiological strain, and contributes to improved comfort during symptomatic periods.

---

Quick Facts: Relief for Allergic Discomfort

Symptom Category	Therapeutic Context	Patient Benefit
Nasal/Ocular Irritation	Acute or chronic rhinitis episodes	May assist with maintaining functional stability during flare-ups
Dermal Pruritus	Recurrent or persistent hives	May help maintain a sense of stability when symptoms are more noticeable

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Yi Fei?

Official regulatory documents define specific populations who are eligible, restricted, or contraindicated for the use of Yi Fei (Loratadine).

Category	Official Regulatory Status
Populations for whom use is allowed	Adults, adolescents, and children geq 2 years of age.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Loratadine or any formulation excipient.
Age-related eligibility rules	Efficacy and safety have not been established in children under 2 years of age.
Condition-specific eligibility rules	Individuals with severe liver impairment or renal insufficiency (GFR < 30 mL/min) require conditional use and a lower initial dose.
Pregnancy and lactation eligibility	Use during pregnancy is preferable to avoid as a precautionary measure. Use is not recommended in breastfeeding women as the drug is excreted in breast milk.
Eligibility-related restriction	Use must be discontinued at least 48 hours prior to allergy skin testing.

Regulatory authorities mandate that Yi Fei is not appropriate for use in infants under 2 years of age. Furthermore, its use is officially restricted in patients with severe hepatic or renal impairment, who require consultation due to potential drug accumulation. These classifications rigorously determine the official eligibility profile.

Yi Fei Interactions with other medicines and products

This section details the interaction patterns for Yi Fei (Loratadine) strictly as documented in official government regulatory information, such as FDA labeling and the European Summary of Product Characteristics (SmPC).

Documented Interactions with Medicines and Products

The primary documented interactions involve the medicine's metabolism, which is mainly dependent on the CYP3A4 and CYP2D6 enzymes. Concurrent use with inhibitors of these enzymes may increase Loratadine levels:

• Exposure-Altering Interactions: The co-administration of Yi Fei with Ketoconazole, Erythromycin, or Cimetidine is formally documented to lead to substantially increased plasma concentrations of Loratadine.

  • Regulatory Note: Despite the pharmacokinetic increase, official regulatory studies reported this change to be without clinically significant findings at the recommended dosage.

• Food Interaction: Ingestion of food is associated with a pharmacokinetic effect that increases the overall exposure (AUC) of Loratadine by approximately 48% and causes a delay in the time to peak concentration ( T max).

• Lack of Alcohol Interaction: Official data confirms that Alcohol does not exhibit potentiating effects on psychomotor performance when administered with Loratadine.

Population-Specific Cautions

A caution is noted for specific patient groups: individuals with hepatic impairment (liver disease) or renal impairment, as well as the elderly, may be at increased risk for somnolence when co-administered with medicines that impair Loratadine's clearance, due to increased exposure.

The primary mechanism involves selective H₁-receptor antagonism in peripheral tissues. Loratadine and its major active metabolite, Descarboethoxyloratadine, competitively bind to the H₁-receptors on cells, such as vascular endothelium and sensory nerve endings . This action prevents the naturally released mediator, histamine, from activating these receptors and initiating its downstream signaling cascade. This peripheral-focused blockade alters the signaling dynamics of local physiological responses to histamine without substantial interaction with central H₁-receptors.

By blocking the H₁-receptors, the drug interferes with the histamine-mediated signals that cause an increase in capillary permeability and stimulate sensory nerve endings. This interruption of the molecular cascade limits the leakage of fluid from blood vessels, which leads to a reduction in localized capillary leakage. The action on sensory nerves increases the stimulation threshold for the histamine pathway. The sustained duration of peripheral receptor antagonism is determined by the prolonged presence and activity of the active metabolite.

How to Use Yi Fei

The administration of Yi Fei, which contains the active ingredient Loratadine, is strictly through the oral route. The standard regimen for adults and children aged six years and older is 10 mg taken once daily, and this dose is not to be exceeded within a 24-hour period. Due to its long-acting profile, a single dose is intended to provide effects over 24 hours, establishing the once-daily frequency pattern.

The medicine may be administered with or without food, as its absorption is not dependent on meal timing. Patients using the oral syrup or solution must utilize a calibrated measuring device to ensure the dosage is precise. For those using the Orally Disintegrating Tablet (ODT) formulation, specific procedural conditions apply: the tablet should be placed directly onto the tongue to dissolve and should not be pushed through the blister foil to avoid damage.

A critical usage constraint involves patients with severe hepatic impairment or severe renal impairment (GFR less than 30 mL/min). In these populations, there is an extension of the dosing interval to 48 hours, meaning the 10 mg dose is taken only every other day. If a scheduled daily dose is missed, the procedure is to skip that dose if the time for the next dose is near, and never to take a double dose to compensate. This procedural structure ensures the standardized and controlled use of the medicine across varied patient contexts.

Research evidence / Overview of Studies for Yi Fei (Loratadine)

---

Evidence for Use in Allergic Rhinitis (Hay Fever and Year-Round Allergies)

YHn Fei (Loratadine) was observed in Randomized Controlled Trials (RCTs), a key study type for clinical research, comparing the medicine against an inactive placebo or other allergy treatments. Research was studied for use in patients diagnosed with seasonal or perennial allergic rhinitis, exploring patterns in symptom variability over time. Studies mainly monitored patient-reported outcomes describing perceived discomfort, such as measurements taken of overall symptom scores that included sneezing, a runny nose, and itching of the eyes and nose.

Studies focused on episodes where symptoms become more noticeable, observing responses over defined time intervals that were typically short-term, such as a few days to a few weeks. Long-term patterns of symptom evolution are not fully established by these initial controlled trials. While the evidence contributes to the broader understanding of symptom patterns, some research has explored measurements related to nasal congestion compared to measurements related to other key symptoms.

---

Evidence for Use in Chronic Idiopathic Urticaria (Persistent Hives)

Yi Fei was studied for use in conditions characterized by fluctuating or episodic manifestations, such as Chronic Idiopathic Urticaria (hives of unknown cause). The research examined how individuals reported changes in outcomes related to physical discomfort, primarily focusing on the severity of the itching (pruritus) and the number and size of the raised skin patches, known as weals. These studies primarily included adults and adolescents, and some trials also involved older children.

Evidence is limited compared to the data available for allergic rhinitis. Research exploring specific dosing strategies beyond the standard recommended amount has been less common for this condition. Furthermore, data for certain groups remain insufficient, especially for long-term use in managing conditions characterized by cycles of stability and flare-ups.

---

What Remains Uncertain and Research Limitations

The vast majority of the core evidence focused on short-term to intermediate-term outcomes, meaning follow-up durations were limited in most key controlled trials, and long-term effects on continuous symptom control are not fully characterized. Additionally, comparative evidence is lacking or findings were mixed when research examined measurements taken across all alternative second-generation treatments and all defined outcomes. Research often shows measurements of differing impacts, such as the generally limited change observed in outcomes related to nasal congestion. Findings describe group patterns, not personal outcomes.

Key Studies & References Loratadine (MedlinePlus Drug Information - National Institutes of Health)

Common questions about Yi Fei (FAQ)

---

Q: Is Yi Fei considered a brand name or a generic name drug?

Yi Fei is the trade name for a product containing the active ingredient loratadine. Loratadine is available globally in many different brand-name and generic formulations. Official product information indicates that generic loratadine may be available.

---

Q: When was Yi Fei first approved by a major regulatory body like the FDA or EMA?

The active ingredient in Yi Fei, loratadine, was first approved by the U.S. FDA in 1993. Since that time, the medicine has gone through various regulatory changes, and its availability status has changed.

---

Q: Is there an authorized generic version of Yi Fei currently available?

Official monographs indicate that loratadine is widely available as a generic medication. The generic form of this drug is available, as noted in public regulatory information.

---

Q: How long does it usually take before I can expect to feel the effects of Yi Fei?

According to official pharmacodynamic studies, the antihistaminic effects of the active ingredient generally begin within one to three hours after taking a single oral dose. The maximum effect is typically observed between 8 and 12 hours after administration.

---

Q: What should I watch for as a sign of a serious adverse reaction to Yi Fei?

Regulatory documents state that while serious side effects are rare, patients should be alert for signs of hypersensitivity (an allergic reaction) to the active substance or excipients. If signs of a hypersensitivity reaction occur, official information advises discontinuing use.

---

Q: Can Yi Fei tablets be crushed or split if swallowing is difficult?

The official labeling provides specific instructions for the use of the syrup and the Orally Disintegrating Tablet (ODT) formulations. Official documents do not include instructions for crushing or splitting the standard tablet formulation.

---

Q: Is there a specific food or drink that must be avoided when taking Yi Fei?

Regulatory information notes that taking the medicine with food increases the overall exposure of the drug in the body. However, official sources do not specify any particular food or drink that is prohibited with this medicine.

---

Q: Does the age of the patient affect how Yi Fei works in the body?

Official regulatory texts note specific considerations for age and health conditions. The potential for somnolence (drowsiness) may be increased in the elderly. Additionally, dose adjustments are explicitly required for both children and adults who have severe kidney or liver impairment.

---

Q: Can Yi Fei cause drowsiness that would affect driving or operating machinery?

Clinical trial data states that the drug has no or negligible influence on the ability to drive or use machines. However, patients are informed that some individuals may very rarely experience drowsiness. Official information notes that this potential for somnolence may be a consideration for patients with severe liver or kidney impairment.

---

Q: Does Yi Fei contain any common allergens like gluten, lactose, or soy?

Product labels for many standard tablet formulations of the active ingredient list lactose as an excipient. Official warnings are present for individuals with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption, indicating that use is restricted for these individuals.

---

Q: Does taking Yi Fei affect the results of routine blood tests or lab work?

Regulatory documents mandate that use of this medicine must be discontinued at least 48 hours prior to allergy skin testing. This is the only mandated restriction related to lab procedures, as the medicine can prevent or reduce the expected reactions on the test.

---

Q: Can Yi Fei be taken safely with over-the-counter pain relievers?

Official documents indicate that the active ingredient is not expected to have major interactions with common non-drowsy pain relievers like acetaminophen or ibuprofen. However, official sources note that patients should consider avoiding combination products that contain other antihistamines, as this could increase the risk of side effects like drowsiness.

---

Q: Why is Yi Fei recommended to be taken at a certain time of day?

The active ingredient is intended to provide continuous effects over 24 hours and is therefore prescribed to be taken once daily. Official product information explicitly states that the tablet may be taken without regard to mealtime and does not mandate a specific time of day for administration.

The storage and disposal of Yi Fei (Loratadine) must adhere strictly to official regulatory guidelines to maintain its stability and ensure safety.

Official Storage Requirements

• Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C. Excessive heat must be avoided.
• Protection: The product must be protected from excessive moisture and kept in its original container with the cap tightly closed.
• Child Safety: Like all medicines, it must be stored out of the reach and sight of children.

Official Disposal Instructions

Unused or expired product should be discarded following local regulations. The preferred method is using an official drug take-back program. If one is unavailable, the medicine may be mixed with an undesirable substance, sealed, and disposed of in household trash. Do not dispose of this medicine in wastewater.